Electrochemical Skin Conductance as a Marker of Painful Oxaliplatin-Induced Peripheral Neuropathy

Table 1

Eligibility criteria of Canaloxa study.

---

Inclusion criteria

---

Patient from the Department of Oncology at Paris Saint Joseph Hospital, male or female, aged over 18.

Patient suffering from any type of cancer, at any stages (estimated according to the TNM classification)

Patients treated with oxaliplatin based regimen for at least 5 cycles (i.e., 10 weeks)

Patients with clinical neuropathy objectified according to the NCI-CTCAE v4.0

---

Non-inclusion criteria

---

Patient with brain or leptomeningeal metastasis

Patient previously treated with cisplatin

Patient addicted to alcohol

Diabetic patient (based on fasting glucose)

Patient receiving calcium or magnesium salts intravenously

Patients with implantable medical devices (pacemakers, implantable defibrillators)

Patient suffering from psychiatric disorders

Patient treated with at least one of the following drug (active in neuropathic pain relieve): venlafaxin, carbamazepin, gabapentin, pregabalin, clomipramin, amitriptylin, imipramin, and duloxetin.

---